Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000556
First received: October 27, 1999
Last updated: December 1, 2005
Last verified: November 2005
  Purpose

To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.


Condition Intervention Phase
Arrhythmia
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Drug: amiodarone
Drug: sotalol
Drug: propafenone
Drug: flecainide
Drug: quinidine
Drug: moricizine
Drug: disopyramide
Drug: procainamide
Drug: adrenergic beta antagonists
Drug: verapamil
Drug: diltiazem
Drug: digoxin
Procedure: catheter ablation
Device: pacemaker, artificial
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: March 1995
Estimated Study Completion Date: September 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Elderly men and women with atrial fibrillation and other risk factors for stroke.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000556

Sponsors and Collaborators
Investigators
Investigator: H. Greene Statistics and Epidemiology Research Corporation (S.E.R.C.)
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000556     History of Changes
Other Study ID Numbers: 100
Study First Received: October 27, 1999
Last Updated: December 1, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Arrhythmias, Cardiac
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Adrenergic Agents
Sotalol
Quinidine
Adrenergic beta-Antagonists
Amiodarone
Propafenone
Verapamil
Digoxin
Disopyramide
Flecainide
Procainamide
Moricizine
Diltiazem
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Adrenergic Antagonists
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Enzyme Inhibitors
Vasodilator Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers

ClinicalTrials.gov processed this record on August 28, 2014